Company Analysis
Sign in

Belite Bio, Inc (BLTE)

Nasdaq: BLTE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.9
◀ Past 5.8● Present 6.4▶ Future 5.5
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$77.6M-114.7%
Earnings per share$-2.31-95.8%
Operating cash flow-$37.0M-26.5%
Cash$353M+1014.2%
Debtn/a
Shareholders’ equity$770M+428.4%
Shares, diluted33.5M+9.8%
Return on equity-10.1%
The recordfrom its filings
Filings in 202670
Newest filingNov 12 · 6-K
Annual reportMar 31, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$40.6M
Insider buys, 12 months$0.00
Patents granted6
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton BLTE · research, not advice